All of the necessary patients have been found and recruited for a phase III study of glepaglutide, which is a potential treatment of short bowel syndrome (SBS), Zealand Pharma announces in a press release on Thursday.
Preliminary data from the trial is expected to be ready in the third quarter of 2022.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.